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Abstract Despite significant improvement in pancreas allo-
graft survival, rejection of the pancreas remains a major clin-
ical problem. In addition to cellular rejection of the pancreas,
antibody-mediated rejection of the pancreas is now a well-
described entity. The 2011 Banff update established compre-
hensive guidelines for the diagnosis of acute and chronic
AMR. The pancreas biopsy is critical in order to accurately
diagnose and treat pancreas rejection. Other modes of moni-
toring pancreas rejection we feel are neither sensitive nor spe-
cific enough. In this review, we examine recent advances in
the diagnosis and treatment of pancreas rejection as well as
describe practical diagnostic and treatment algorithms.
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Introduction
Solid organ pancreas transplant outcomes continue to improve
[1], with the half-life of simultaneous pancreas and kidney
(SPK) allograft approaching 15 years and that of solitary pan-
creas recipients nearing 13 years [2]. Much of this success can
likely be attributed to improved surgical technique, immuno-
suppression, and diagnosis and treatment of rejection. In this
review, we will specifically focus on recent advances in the
diagnosis and treatment of pancreas rejection.
Clinical Presentation of Rejection
Clinically, pancreas allograft function is commonly monitored
by a number of parameters including hyperglycemia, serum
amylase, serum lipase, C-peptide level, hemoglobin A1C, or,
if bladder drained, urinary amylase. However, in order to ac-
curately identify and define rejection, these clinical tools are
insufficient, because they are too non-specific. There are mul-
tiple potential causes for hyperamylasemia, hyperlipasemia,
and hyperglycemia. Even stable kidney function, or a normal
serum creatinine in SPK transplants, is not a consistently reli-
able indicator that pancreatic graft immunological damage is
not occurring [4]. Indeed, it is not uncommon to observe iso-
lated pancreas rejection in the setting of normal kidney allo-
graft function (Table 1).
Elevated pancreatic enzymes is the most common pre-
sentation of pancreatic allograft rejection, and most pa-
tients are asymptomatic or have only mild graft tenderness
upon presentation. If a patient is asymptomatic, the source
of the elevated enzymes is more likely to be from the
transplanted pancreas as the graft itself is insensate. In
contrast, symptomatic increases in pancreatic enzymes
can point to either transplant or native gland disease. Li-
pase is considered to be more specific than amylase and
has greater sensitivity in the author’s experience. Naturally,
these signs and symptoms can arise from multiple causes in
the setting of an enterically drained graft. Hence, it is use-
ful to consider the differential diagnosis and the timing of
presentation when evaluating these patients (Fig. 1,
Table 2).
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An algorithm for the diagnosis and management of patients
with increased pancreatic enzymes is shown in Fig. 2 [3•]. In
our practice, the initial approach to the patient with elevated
enzymes is history and physical, fasting C-peptide, HbA1C,
donor-specific antibodies (DSA), and an imaging study, pref-
erably CT scan of the abdomen and pelvis with IV and PO
contrast (Fig. 2). In the perioperative period (<45 days) or in
the presence of abdominal symptoms, it is important to obtain
a CT scan first before allograft biopsy to evaluate for postsur-
gical complications or intra-abdominal infection. On the other
hand, if the patient is beyond the perioperative period and
without abdominal symptoms, a surgical cause for the elevat-
ed enzymes is significantly less likely, and therefore, it is
reasonable to go straight to pancreas allograft biopsy and as-
sess the graft for anatomical abnormalities during perfor-
mance of the biopsy. Regardless of the time frame
posttransplant, a pancreas allograft biopsy and CT scan will
efficiently identify the cause for elevated pancreatic enzymes
in the vast majority of cases.
Medication non-compliance, recent intolerance of oral
medications, alcohol consumption, recent abdominal trauma,
constipation, presence of a ventral hernia, abdominal pain,
nausea, vomiting, and obstructive symptoms are important
points to elicit from the patient. Duodenal or parenchymal
enzyme leak, pseudocyst, mycotic aneurysm, SBO, intrinsic
pancreatic abnormalities such as duct strictures, and tumors
are included in the differential diagnosis of elevated enzymes
and are usually diagnosed with imaging studies.
In our experience, transplant pancreatitis that is not
attributable to an anatomic or immunological cause is
very uncommon. Instead, transplant pancreatitis, putative-
ly defined as increased pancreatic enzymes without evi-
dence of other anatomic abnormality on CT scan other
than peri-pancreatic transplant inflammation and graft
swelling, can also be indicative of acute or chronic rejec-
tion or CMV pancreatitis. In our large series of for-cause
pancreas allograft biopsies, non-immunological pancreati-
tis was only diagnosed on biopsy in 4 % (16/422) of
biopsies, a frequency similar to that reported previously
[4]. Therefore, transplant pancreatitis should be consid-
ered a diagnosis of exclusion (Table 1).
While most patients who have acute rejection present with
elevated pancreatic enzymes, it is not uncommon to see pa-
tients develop chronic rejection and graft failure without sig-
nificant increases in their serum enzymes. Why chronic rejec-
tion does not always coincide with serological evidence of
acinar injury is not presently known, but may be related to
progressive loss of acinar/parenchymal tissue resulting in less
release of enzymes and/or reduced lab frequency resulting in
missed detection.
Table 1 Pancreas allograft biopsies at the University of Wisconsin
from January 1994 to July 2012
Total 422
Percutaneous 406 (96.2 %)
Rejection (of any kind) 265 (62.8 %)
With normal amylase and lipase 20 (7.5 %)
Pancreatitis 16 (3.8 %)
Non-diagnostic 24 (5.7 %)
Simultaneous pancreas and kidney biopsies 20
Discordant for rejection 5 (25 %)
Fig. 1 Temporal relationship of elevated pancreas enzymes to etiology.
Surgical complications typically present early in the postoperative course,
whereas rejection most commonly presents later. BOther^ includes
possible causes such as transplant pancreatic duct stricture, native
pancreatitis, IPMN or cancer in pancreas transplant or native pancreas,
and penetrating ulcer. Of note, although complete graft thrombosis can
present as increased pancreatic enzymes, in our experience, this is a very
uncommon presentation, and when most grafts thrombose, very limited
increases in enzymes are seen if at all. Relative probability on the Y-axis
does not represent the overall probability or incidence of this
complication; instead, it strives to convey the relative probability that
these diagnoses are associated with elevated pancreatic enzymes.
Abbreviations: ACR/AMR acute cellular rejection/antibody-mediated
rejection, Ent/Pa Leak enteric or pancreatic leak, SBO small bowel
obstruction
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Pancreas Allograft Biopsy
In order to diagnose pancreas rejection accurately, a biopsy of
the pancreas allograft is necessary. It is currently the only
available means of grading the severity of rejection and
distinguishing antibody-mediated rejection (AMR) from acute
cellular rejection (ACR). The most commonly performed ap-
proach to allograft biopsy is percutaneous ultrasound-guided
biopsy of the pancreas parenchyma, which can be performed
in either bladder-drained or enterically drained allografts safe-
ly and effectively [5, 6]. Alternative methods of acquiring
tissue from the pancreaticoduodenal allograft have been de-
scribed. These include percutaneous CT-guided biopsy, endo-
scopic biopsy of the donor duodenum for enterically drained
pancreata, or, if bladder drained, cystoscopic needle biopsy of
pancreatic head and/or mucosal biopsy of the donor duode-
num. The potential for discordant findings between pancreas
histology and duodenal histology [7–9] has limited the wide-
spread reliance of sampling duodenal mucosa for diagnosis.
Furthermore, C4d staining features characteristic of AMR in
the duodenal mucosa have not been adequately defined, and
current methods for staining duodenal mucosal biopsies for
C4d may not be sufficiently specific. Additionally, using the
kidney as a sentinel organ, as can be done in SPK transplants,
can be misleading. In our experience, ∼25 % of kidney and
pancreas biopsies in SPK patients are discordant (Table 1).
Prior studies have demonstrated that isolated pancreas rejec-
tion with normal renal function in SPK patients is not uncom-
mon [4, 10]. Therefore, we advocate for an actual core biopsy
of pancreatic tissue to rule out rejection.
In our practice, we prefer ultrasound-guided biopsy with
an 18-gauge automatic biopsy device. Our trajectory for
biopsy is ideally towards the tail, avoiding the splenic ar-
tery and vein. Because of the nest of vessels and larger duct
in the head region, we prefer to biopsy the body/tail of the
graft aiming either transversely or preferably longitudinal-
ly with respect to the axis of the pancreas. We have per-
formed 406 percutaneous biopsies since 1992, with a very
low complication rate and no graft losses. Two patients
required reoperation: one for bleeding and one for evacu-
ation of pancreatic ascites, which ultimately resolved, and
both patients currently still retain excellent graft function.
If we are unsuccessful, or there is no suitable safe window
free of overlying bowel, then we proceed with CT-guided
Table 2 Common diagnoses
contributing to increased
pancreatic enzymes after pancreas
transplantation
Diagnosis Overall frequency (%) Frequency the entity presents
as increased enzymes
Perioperative (<45 days)
Enzyme leak1 ∼5 High
Infected fluid/abscess ∼5 Moderate
Thrombosis 2–5 Low
Ileus 5–10, transient Moderate
Acute rejection 1–2 High
Mid postoperative (>45 days–1 year)





CMV pancreatitis ∼1 High
Late postoperative (>1 year)
Acute rejection 5–10 High
Chronic rejection ∼5 Moderate–high
SBO/ventral hernia ∼10 Low–moderate
Intrinsic pancreatic abnormalityb ∼5 Moderate–high
Native pancreatitis 1 High
CMV pancreatitis <1 High
1 Enzyme leak—enteric or parenchymal, including pseudocyst or pancreatic ascites
a Frequency depends on risk factors such as type of transplant, primary vs. re-transplant, sensitized status, donor-
specific antibody, race mismatch, and donor age
b Includes graft trauma, chemical pancreatitis, pancreatic duct stricture, IPMN, carcinoma, pseudocyst
Abbreviations: SBO small bowel obstruction, CMV cytomegalovirus
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biopsy using a posterior approach, or alternatively an open
or laparoscopic biopsy, but this is required rarely. The ma-
jority of pancreas biopsies were diagnostic, only 6 % (24/
422) were non-diagnostic (Table 1).
Distinguishing Histologic Features of AMR, ACR,
and Pancreatitis
The 2007 Banff guidelines for the diagnosis of pancreas re-
jection solidified prior histopathological descriptions and fo-
cused on ACR [11–13]. However, in response to reports in the
literature documenting pancreas AMR, the 2011 Banff update
established comprehensive guidelines for diagnosis of acute
and chronic AMR [14] of the pancreas (Table 3). While a
complete review of current histopathological criteria of rejec-
tion is beyond the scope of this review, suffice it to say that the
only definitive way to precisely diagnosis the severity and
mechanism of pancreas allograft rejection is with a pancreas
biopsy. In our series of 422 for-cause biopsies, 63 % were
diagnostic for rejection; only 4 % were determined to be graft
pancreatitis (Table 1).
Incidence and Risk Factors for Rejection
Niederhaus et al. recently reported on the frequency of both
cellular and antibody-mediated pancreas allograft rejection as
they relate to specific risk factors [15••]. The incidence of
rejection within 1-year posttransplant in a cohort of 162 pa-
tients of all pancreas transplant types including many re-
transplants was 21 %, with antibody-mediated rejection
(AMR), acute cellular rejection (ACR), and mixed rejection
occurring in nearly equal frequency. In their study, the major-
ity of pancreas rejection episodes were successfully reversed
and graft function was maintained; however, 20 % of grafts
were lost within a year of diagnosis.
Dong et al. similarly showed a 1-year acute rejection rate of
14.7 % increasing to 26.6 % by 5 years posttransplant [16].
The findings of Dong et al. also support the notion that allo-
graft rejection even if diagnosed and treated aggressively is
associated with pancreas graft failure in a subset of patients
especially if diagnosed beyond 3 months posttransplant [11].
Risk factors for rejection identified in these two studies
include non-primary SPK transplants, primary solitary pancre-
as alone (PTA), race mismatch [10], and increasing donor age
[15••, 16]. Increased vigilance for rejection in these scenarios,
Fig. 2 The University ofWisconsin Diagnosis and Treatment Algorithm
Abbreviations: DSA donor-specific antibody, ACMR acute cell-mediated
rejection, aAMR acute antibody-mediated rejection, cAMR chronic
antibody-mediated rejection, ATG anti-thymocyte globulin, IVIg
intravenous immunoglobulin, PP plasmapheresis. [(Published in Trends
in Transplantation, © Permanyer Publications) 2].
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which are associated with higher immunological risk, may
therefore be warranted.
Donor-Specific Antibody as a Biomarker
of Rejection
The deleterious effects of both pre-formed donor-specific an-
tibodies (DSA) and de novo DSA are well established in the
kidney transplant literature [17]. Few studies, however, have
directly evaluated the role of DSA in pancreas transplantation.
Cantarovich et al. showed that DSA in SPK transplants was an
independent predictor of graft failure. Of their patients, 24 %
(40/167, 152 were SPK recipients) were found to have DSA
postoperatively. Maintenance therapy was with anti-
thymocyte globulin, tacrolimus, and mycophenolate mofetil
only. This study identified DSA as an independent predictor
of graft failure [18]. However, DSAwas not quantified in all
patients preoperatively so it is unclear from this study what
proportion of recipients developed de novo DSA vs. those
who already had pre-formed DSA.
Mittal et al. demonstrated in a large cohort of pancreas
transplant patients that de novo DSAwas also an independent
risk factor for graft loss [19•]. In this study of 439 pancreas
transplant patients (73 % SPK), de novo DSA developed in
37.9 % of patients of the patients who had follow-up. The
DSA MFI cutoff was 1000. Pancreas biopsies in association
with elevated DSAwere not reported in this study. The immu-
nosuppressive regimen consisted of alemtuzumab induction
followed by MMF and tacrolimus maintenance immunosup-
pression. Steroids were not used as maintenance therapy. This
is a surprisingly high rate of de novo DSA, and one wonders if
it was causally associated with this alemtuzumab/steroid-free
immunosuppressive regimen. There are other reports of
alemtuzumab associated with increased DSA production in
kidney transplant recipients, which may explain such an ele-
vated incidence of de novo DSA [20]. Obviously, this area
requires further study to understand the exact mechanisms of
these observations, especially the association and timing of de
novo DSA in relation to histopathological rejection. But none-
theless, strategies to prevent or reduce de novo DSA may lead
to better graft outcomes.
Table 3 Banff 2011 classification of cell- and antibody-mediated
rejection of the pancreas
1. Acute T cell-mediated rejection
Grade I/mild acute T cell-mediated rejection—active septal inflammation
(activated, blastic lymphocytes, and ±eosinophils) involving septal
structures: venulitis (subendothelial accumulation of inflammatory
cells and endothelial damage in septal veins, ductitis (epithelial
inflammation and damage of ducts)
and/or
Focal acinar inflammation. No more than two inflammatory foci per
lobule with absent or minimal acinar cell injury
Grade II/moderate acute Tcell-mediated rejection (requires differentiation
from AMR)
Multifocal (but not confluent or diffuse) acinar inflammation (≥3 foci per
lobule) with spotty (individual) acinar cell injury and dropout
and/or
Mild intimal arteritis (with minimal, <25 % luminal compromise)
Grade III/severe acute T cell-mediated rejection (requires differentiation
from AMR)
Diffuse (widespread, extensive) acinar inflammation with focal or diffuse
multicellular/confluent acinar cell necrosis and/or moderate or severe




(a) Confirmed circulating donor-specific antibody (DSA)
(b) Morphological evidence of tissue injury (interacinar inflammation/
capillaritis, acinar cell damage, swelling/necrosis/apoptosis/dropout,
vasculitis, thrombosis)
(c) C4d positivity in interacinar capillaries (IAC, ≥5 % of acinar
lobular surface)
Acute AMR 3 of 3 diagnostic components
Consistent with acute AMR 2 of 3 diagnostic components
Requires exclusion of AMR 1 of 3 diagnostic components
See below for histological grading of acute AMR
Chronic active antibody-mediated rejection: combined features of
categories 1 and 2 in the absence of features of ACMR
3. Chronic allograft rejection/graft fibrosis
Stage I (mild graft fibrosis)
Expansion of fibrous septa; the fibrosis occupies less than 30 % of the
core surface but the acinar lobules have eroded, irregular contours. The
central lobular areas are normal
Stage II (moderate graft fibrosis)
The fibrosis occupies 30–60 % of the core surface. The exocrine
atrophy affects the majority of the lobules in their periphery (irregular
contours) and in their central areas (thin fibrous strands crisscross
between individual acini)
Stage III (severe graft fibrosis)
The fibrotic areas predominate and occupy more than 60 % of the core
surface with only isolated areas of residual acinar tissue and/or islets
present
Histological grading of acute AMR
Grade I/mild acute AMR
Well-preserved architecture, mild monocytic-macrophagic or mixed
(monocytic-macrophagic/neutrophilic) infiltrates with rare acinar cell
damage
Grade II/moderate acute AMR
Overall preservation of the architecture with interacinar monocytic-
macrophagic or mixed (monocytic-macrophagic/neutrophilic)
infiltrates, capillary dilatation, capillaritis, congestion, multicellular
acinar cell dropout, and extravasation of red blood cells
Table 3 (continued)
Grade III/severe acute AMR
Architectural disarray, scattered inflammatory infiltrates in a
background of interstitial hemorrhage, multifocal and confluent
parenchymal necrosis, arterial and venous wall necrosis, and thrombosis
(With permission from: Drachenberg CB, Torrealba JR, Nankivell BJ,
Rangel EB, Bajema IM, Kim DU, et al. Guidelines for the diagnosis of
antibody-mediated rejection in pancreas allografts—updated Banff grad-
ing schema. American Journal of Transplantation. 2011;11 (9):1792–
802)]]
Curr Transpl Rep (2015) 2:169–175 173
In our practice, the presence of pretransplant DSA aids our
assessment of the posttransplant immunologic risk. For pa-
tients with pretransplant DSA and a negative flow crossmatch,
we tend to favor using a depleting antibody for induction
therapy. We monitor all our patients with DSA measurements
postoperatively with the frequency of monitoring determined
by a preoperative risk stratification. However, it is currently
unknown what to do with de novo DSA in the setting of
normal pancreas allograft function. One hypothesis is that it
indicates under immunosuppression, and increasing immuno-
suppression maybe warranted. Elevated DSA in the setting of
normal graft function could also be a harbinger of eventual
graft dysfunction or simply could be of no clinical conse-
quence. Certainly more studies are needed. If the emergence
or rise in DSA does in fact accompany abnormal graft func-
tion, then a biopsy is warranted to rule out rejection.
Treatment of Pancreas Rejection
A normal fasting C-peptide and HbA1c confirms a function-
ing pancreas allograft prior to the initiation of anti-rejection
therapy. Consideration of pancreas graft functional reserve
prior to initiating any anti-rejection therapy is paramount. Hy-
perglycemia, as evidenced by significantly elevated fasting
blood glucose or HbA1c, or low fasting C-peptide level
should be taken into account when weighing the potential
benefits and risks of pursuing therapy. Additionally, a signif-
icant chronic component to the patient’s rejection status, as
evidenced by fibrotic changes on biopsy, should factor into
the potential benefit of therapy. Treatment of chronic or acute
rejection if significant hyperglycemia is present prior to initi-
ation of steroid therapy, or if the patient is on insulin, is con-
troversial, but traditionally, hyperglycemia had been thought
to be a marker of poor salvagability in a pancreas allograft
[12]. If the patient’s graft dysfunction has progressed to the
point of requiring large doses of exogenous insulin, forgoing
treatment for rejection should be considered, especially since
several therapeutic agents will only exacerbate hyperglyce-
mia. If the graft has evidence of significant fibrosis, and/or a
paucity of islets and/or is small on imaging, and C-peptide is
low, then chronic rejection is probable and little will be gained
with treatment, or until at least better therapies are developed.
On the other hand, if the patient has only minimal fibrosis and
primarily acute changes, with detectable normal appearing
islets, imaging that shows a normal-sized gland, and fasting
C-peptide is easily detectable well into the normal range, then
it is worth treating the rejection process aggressively in our
experience even with the short-term prospect of worsening
glycemic control and temporary insulin use.
H&E staining can diagnose and grade ACR, and we treat
accordingly with steroids +/− anti-thymocyte globulin (ATG)
as illustrated in Fig. 2. It is important to note that, if ACR is
present, it should be treated aggressively. In the setting of
mixed cellular and AMR, we recommend that initial therapy
be directed against the cellular component. Niederhaus et al.
found, even in cases of mixed rejection, the pancreas graft
survival mirrored that of ACR alone if treated [15••]. The
incidence of mixed rejection is not trivial, occurring in 7 %
of recipients at 1 year. At this time, it is unclear if mixed
rejection requires IVIG, plasmapheresis, and/or specific anti-
B cell therapies or if steroids and ATG is sufficient. If the
biopsy is negative or indeterminate for ACR, we await results
of C4d immunostaining and DSA, which usually takes a day
or two longer in our laboratory.
If DSA is positive with histologic findings consistent with
AMR, even in the absence of C4d, we proceed with treatment
consisting of IVIG and plasmapheresis as we would in the
setting of significant C4d staining. In cases of a mixed rejec-
tion, we generally add ATG. If the amylase/lipase decline, we
continue treatment until they have normalized. If their descent
stalls or if they start to rise again, we usually repeat the biopsy.
If the re-biopsy demonstrates persistent AMR, additional anti-
B cell therapies, such as bortezomib, rituximab, or
eculizumab, are considered. Admittedly, treatment of pancreas
AMR is currently pursued without clear data and the afore-
mentioned approach is merely proposed as a guide. Even in
the kidney AMR literature, there is a paucity of randomized
clinical trails. Despite this, there have been advances in the
treatment of AMR resulting in improved outcomes. The main
treatment goal in AMR is for the reduction of DSA and elim-
ination of the B cell and plasma cell population responsible for
the production of DSA. Hopefully, carefully protocolized
treatments and the examination of outcomes will be prospec-
tively conducted.
Overall, key points of our treatment algorithm (Fig. 2) are
as follows: ensure the pancreas is still functioning and there-
fore worthy of salvage, obtain tissue diagnosis to evaluate the
degree of ACR and AMR, and treat ACR aggressively as a
first and primary strategy. Sequentially, escalate therapy as
data becomes available and/or if there is no improvement in
enzymes with ACR-directed treatment. Finally, if there is any
doubt as to the cause of ongoing enzyme elevation or hyper-
glycemia, it is valuable to consider re-biopsy. While we ac-
knowledge this field is still evolving, we believe the afore-
mentioned approach is a reasonable management protocol
(Fig. 2).
Conclusions
In our practice of evaluating each patient for the possibility of
pancreas graft rejection, we gather serologic and histologic
data in the form of DSA and biopsy, and if hyperglycemic,
then fasting C-peptide and HbA1c. Once a diagnosis of rejec-
tion is made, we treat accordingly as described in Fig. 2 for
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ACR, AMR, and mixed types of rejections, as long as the
pancreas is worth saving (i.e., no evidence of hyperglycemia
or elevated HbA1c). One strategy is to use currently available
anti-T and anti-B cell-directed therapies sequentially, progres-
sively escalating therapies over the course of several days to a
week, depending on the response and relative contribution of
each component to the active rejection process. However, it
should also be kept in mind that clear data is lacking in this
area. Moving forward, more rigorous study is required to de-
fine the best treatment regimens for rejection.
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